Clarivate Reveals Medtech Breakthroughs Driving Growth in Pulsed Field Ablation Market
Clarivate (NYSE:CLVT) has published a new e-book analyzing breakthroughs in the pulsed field ablation (PFA) market for atrial fibrillation treatment. PFA technology uses high-voltage microsecond electrical pulses instead of thermal energy, offering safer and more effective procedures compared to traditional methods.
The report highlights significant market growth projections, with PFA expected to grow from $300 million (5% market share) in 2023 to $8 billion (70% market share) by 2028. Key developments include Johnson & Johnson's VARIPULSE FDA approval in November, though its U.S. rollout was paused due to safety concerns. Abbott Laboratories is anticipated to receive FDA approval by mid-2026.
International markets show strong adoption, particularly in Asia Pacific, where the market is projected to exceed $1 billion in 3-5 years, with Japan alone potentially reaching $300 million by 2028.
Clarivate (NYSE:CLVT) ha pubblicato un nuovo e-book che analizza le innovazioni nel mercato dell'ablazione a campo pulsato (PFA) per il trattamento della fibrillazione atriale. La tecnologia PFA utilizza impulsi elettrici ad alta tensione della durata di microsecondi invece dell'energia termica, offrendo procedure più sicure ed efficaci rispetto ai metodi tradizionali.
Il rapporto mette in evidenza prospettive di significativa crescita del mercato, con la previsione che la PFA cresca da 300 milioni di dollari (5% di quota di mercato) nel 2023 a 8 miliardi di dollari (70% di quota di mercato) entro il 2028. I principali sviluppi includono l'approvazione da parte della FDA del VARIPULSE di Johnson & Johnson in novembre, anche se il suo lancio negli Stati Uniti è stato sospeso a causa di preoccupazioni per la sicurezza. Si prevede che Abbott Laboratories riceverà l'approvazione della FDA entro metà del 2026.
I mercati internazionali mostrano una forte adozione, in particolare nella regione Asia-Pacifico, dove il mercato è previsto superare 1 miliardo di dollari in 3-5 anni, con il Giappone che potrebbe raggiungere 300 milioni di dollari entro il 2028.
Clarivate (NYSE:CLVT) ha publicado un nuevo libro electrónico que analiza los avances en el mercado de la ablación por campo pulsado (PFA) para el tratamiento de la fibrilación auricular. La tecnología PFA utiliza pulsos eléctricos de microsegundos de alta tensión en lugar de energía térmica, ofreciendo procedimientos más seguros y efectivos en comparación con los métodos tradicionales.
El informe destaca proyecciones de crecimiento significativas para el mercado, con la PFA que se espera crezca de 300 millones de dólares (5% de cuota de mercado) en 2023 a 8 mil millones de dólares (70% de cuota de mercado) para 2028. Los desarrollos clave incluyen la aprobación de la FDA del VARIPULSE de Johnson & Johnson en noviembre, aunque su lanzamiento en EE. UU. se detuvo debido a preocupaciones de seguridad. Se anticipa que Abbott Laboratories recibirá la aprobación de la FDA a mediados de 2026.
Los mercados internacionales muestran una fuerte adopción, especialmente en Asia-Pacífico, donde se proyecta que el mercado supere 1 mil millones de dólares en 3-5 años, con Japón solo alcanzando potencialmente 300 millones de dólares para 2028.
Clarivate (NYSE:CLVT)는 심방 세동 치료를 위한 펄스 필드 절제술(PFA) 시장의 혁신을 분석한 새로운 전자책을 발표했습니다. PFA 기술은 열 에너지 대신 마이크로초 전압의 전기 펄스를 사용하여 기존 방법보다 더 안전하고 효과적인 절차를 제공합니다.
보고서는 PFA가 2023년 3억 달러 (5% 시장 점유율)에서 2028년까지 80억 달러 (70% 시장 점유율)로 성장할 것으로 예상되는 중요한 시장 성장 전망을 강조합니다. 주요 개발 사항으로는 Johnson & Johnson의 VARIPULSE가 11월에 FDA 승인을 받았지만, 미국에서의 출시가 안전 문제로 중단되었습니다. Abbott Laboratories는 2026년 중반까지 FDA 승인을 받을 것으로 예상됩니다.
국제 시장은 특히 아시아 태평양 지역에서 강한 수용성을 보이며, 이 지역의 시장은 3-5년 내에 10억 달러를 초과할 것으로 예상되며, 일본만으로도 2028년까지 3억 달러에 이를 것으로 보입니다.
Clarivate (NYSE:CLVT) a publié un nouvel e-book analysant les innovations sur le marché de l'ablation par champ pulsé (PFA) pour le traitement de la fibrillation auriculaire. La technologie PFA utilise des impulsions électriques à haute tension d'une durée de microsecondes au lieu de l'énergie thermique, offrant des procédures plus sûres et plus efficaces par rapport aux méthodes traditionnelles.
Le rapport met en lumière des prévisions de croissance significatives pour le marché, avec une PFA qui devrait passer de 300 millions de dollars (5 % de part de marché) en 2023 à 8 milliards de dollars (70 % de part de marché) d'ici 2028. Parmi les développements clés, on trouve l'approbation par la FDA du VARIPULSE de Johnson & Johnson en novembre, bien que son lancement aux États-Unis ait été suspendu en raison de préoccupations de sécurité. Abbott Laboratories devrait obtenir l'approbation de la FDA d'ici la mi-2026.
Les marchés internationaux montrent une forte adoption, notamment dans la région Asie-Pacifique, où le marché devrait dépasser 1 milliard de dollars dans 3-5 ans, le Japon pouvant atteindre 300 millions de dollars d'ici 2028.
Clarivate (NYSE:CLVT) hat ein neues E-Book veröffentlicht, das Durchbrüche im Markt für pulsfeldgestützte Ablation (PFA) zur Behandlung von Vorhofflimmern analysiert. Die PFA-Technologie verwendet hochvoltage Mikrosekunden elektrische Impulse anstelle von thermischer Energie und bietet sicherere und effektivere Verfahren im Vergleich zu traditionellen Methoden.
Der Bericht hebt signifikante Wachstumsprognosen für den Markt hervor, wobei die PFA voraussichtlich von 300 Millionen Dollar (5 % Marktanteil) im Jahr 2023 auf 8 Milliarden Dollar (70 % Marktanteil) bis 2028 wachsen wird. Zu den wichtigsten Entwicklungen gehört die FDA-Zulassung von VARIPULSE durch Johnson & Johnson im November, obwohl der Rollout in den USA aufgrund von Sicherheitsbedenken pausiert wurde. Abbott Laboratories wird voraussichtlich bis Mitte 2026 die FDA-Zulassung erhalten.
Internationale Märkte zeigen eine starke Akzeptanz, insbesondere im asiatisch-pazifischen Raum, wo der Markt voraussichtlich in 3-5 Jahren 1 Milliarde Dollar überschreiten wird, wobei Japan allein bis 2028 voraussichtlich 300 Millionen Dollar erreichen könnte.
- Projected market growth from $300M to $8B by 2028
- Market share expected to increase from 5% to 70% by 2028
- Strong international market expansion, especially in Asia Pacific
- Higher success rates and reduced recurrence rates compared to traditional methods
- Johnson & Johnson's VARIPULSE rollout paused due to neurovascular events
- Abbott Laboratories delayed market entry with FDA approval not expected until mid-2026
Insights
The Pulsed Field Ablation (PFA) market is experiencing unprecedented growth dynamics that warrant investor attention. The projected 26-fold increase in market value from
Several critical market dynamics deserve emphasis:
- The Asia Pacific region emerges as a important growth driver, with Japan alone projected to reach
$300 million by 2028. China's competitive landscape, featuring domestic manufacturers, creates both opportunities and challenges for global players. - Johnson & Johnson's recent pause of VARIPULSE rollout due to safety concerns highlights regulatory risks but also underscores the opportunity for competitors like Abbott Laboratories to gain market share.
- The technology's superior safety profile and efficiency compared to traditional methods (cryoablation and RF ablation) suggests sustainable competitive advantages, supporting the projected market share growth from
5% to over70% .
For Clarivate, this market evolution presents significant opportunities through their market intelligence services. The company's strategic positioning to provide critical insights in this rapidly evolving sector could drive increased demand for their specialized research and analytics services, particularly as competition intensifies and market participants seek strategic advantages.
New e-book explores transformative medtech advancements in pulsed field ablation for atrial fibrillation treatment
Cryoablation and radiofrequency (RF) ablation can cause damage to non-targeted tissues, such as the pulmonary vein, esophagus and phenic nerve. As a result, PFA has emerged as an appealing alternative for treating atrial fibrillation, attracting significant investment from companies worldwide. The technology leverages high-voltage, microsecond electrical pulses rather than thermal energy, enabling a safer, faster procedure with higher success rates and reduced recurrence rates. Consequently, electrophysiologists are rapidly switching to PFA and away from RF and cryoablation.
Juliane Ray, General Manager, Medtech, Life Sciences and Healthcare, Clarivate, said: "The evolution of cardiac ablation is at a pivotal moment, with pulsed field ablation emerging as a breakthrough that is reshaping treatment guidelines and expanding patient access worldwide. As clinical evidence continues to build, we are seeing a shift toward ablation as a first-line therapy, reinforcing the need for innovation in mapping, delivery systems, and procedural efficiency. This e-book explores the latest advancements and market dynamics, equipping stakeholders with the insights needed to anticipate the next wave of transformation in cardiac care."
Andrew Lee, Vice President, Medtech, Life Sciences and Healthcare, Clarivate, said: "The rapid adoption of pulsed field ablation underscores its transformative potential in cardiac care, reshaping the treatment landscape and expanding access for patients worldwide. This e-book provides cardiologists and medical device companies with a comprehensive view of the latest advancements and trends, equipping them with the insights needed to navigate this evolving market. As PFA drives unprecedented growth and innovation, staying informed is crucial for making strategic decisions that align with this dynamic and rapidly expanding sector."
Anette Boyle, Editor, BioWorld, Clarivate, said: "PFA may be the most significant Medtech advance in cardiology in the last decade – and it has certainly been the most rapidly adopted. With the total number of cardiac ablation procedures for atrial fibrillation expected to double in the next two to three years, major players and start-ups alike are racing to complete clinical trials and gain regulatory approvals. We expect to see brisk M&A in this area as companies lagging in development of their own products seek to leapfrog the competition and secure a slice of this hot market."
Key updates and the forecast of the global PFA market featured in Pulsed field ablation: stunning growth shocks the atrial fibrillation market, include:
- Key players: Companies and PFA systems, including FARAPULSE, Affera Sphere-9 and PulseSelect, gained regulatory approvals around the world and even more began clinical trials in 2024. While Johnson & Johnson's VARIPULSE received FDA approval in November, the company indefinitely paused its limited
U.S. rollout to investigate multiple neurovascular events associated with its use in January. Abbott Laboratories, the last of the big four players in the market to gainU.S. marketing authorization, completed enrolment in its VOLT-AF pivotal trial in October and could receive FDA approval as early as mid-2026, with CE mark likely in early 2025. - Rapid expansion in international markets: PFA adoption grew exponentially with FDA approvals in the
U.S. in late 2023 and early 2024. MainlandChina ,Japan andAustralia all have three approved PFA systems, and the market for PFA in theAsia Pacific region is expected to surpass$1 billion China has several domestic manufacturers in the mix, making it a more competitive landscape for global firms.Japan alone could become a$300 million - Market value forecast: From a base of
$300 million 5% of the atrial fibrillation market, Clarivate expects PFA to approach$8 billion 70% of the global atrial fibrillation market by 2028.
Pulsed Field Ablation: Stunning Growth Shocks the Atrial Fibrillation Market, offers an in-depth analysis of recent breakthroughs and the transformative potential of PFA technology featuring insights from the editor of BioWorld MedTech, Annette Boyle, and up-to-the-minute analysis from Clarivate's Medtech experts.
To learn more about the Clarivate e-book, visit here.
To track developments in cardiac ablation and other medical technologies on a daily basis, subscribe to BioWorld MedTech, here: BioWorld MedTech: The Daily Medical Technology News Source.
The Electrophysiology Mapping and Ablation Device Market Insights series provides a comprehensive global market view with granular insights into market dynamics in the broader ablation market as well as the game-changing potential of PFA technology. Designed to ensure our customers have the most current and actionable data to guide their strategic decisions and drive progress toward a healthier future, the series draws on the expertise of Clarivate's Medtech analysts, who leverage proprietary Clarivate Medtech Intelligence data, including Real World Data assets like claims data and PriceTrack. For the latest forecasts for Electrophysiology Mapping and Ablation Device geographical markets, see our Medtech Insights reports, here: Medtech Insights | Clarivate
About BioWorld
With writers and editors stationed around the globe, BioWorld MedTech, published by Clarivate, reports the breaking news and provides key perspective on thousands of innovative medical technologies and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes. The BioWorld group of news services (BioWorld, BioWorld Science, BioWorld MedTech and BioWorld Asia) has a long tradition of excellence in journalism. Collectively, the news services have been honored with 70 awards dating back to 1998.
About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
Media Contact:
Luna Ivkovic,
External Communications, Life Sciences & Healthcare
newsroom@clarivate.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/clarivate-reveals-medtech-breakthroughs-driving-growth-in-pulsed-field-ablation-market-302366544.html
SOURCE Clarivate Plc
FAQ
What is the projected market value for PFA technology by 2028 according to Clarivate (CLVT)?
Why was Johnson & Johnson's VARIPULSE PFA system rollout paused in 2025?
When is Abbott Laboratories expected to receive FDA approval for their PFA system?
What is the projected market value for PFA in Japan by 2028?
How does PFA technology differ from traditional ablation methods?
